Neumora Therapeutics, Inc. (NMRA)

9,45 -0,32 (-3,22%) A partir del 10:06AM EDT. Mercado abierto.

Neumora Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
857 760 0900
https://www.neumoratx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 120

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Paul L. Berns	Co-Founder & Executive Chairman	1,65M	N/A	1967
Mr. Henry O. Gosebruch	President, CEO & Director	3,33M	N/A	1973
Mr. Jason G. Duncan	Chief Legal Officer	315k	N/A	1974
Mr. Robert Lenz M.D., Ph.D.	Head of Research & Development	770,29k	N/A	1971
Ms. Carol Suh	Co-Founder & COO	N/A	N/A	1990
Dr. Robert Michael Poole FACP, M.D.	Co-Founder & Advisor	N/A	N/A	1958
Dr. Joshua Pinto Ph.D.	Chief Financial Officer	876,64k	N/A	1985
Mr. Michael Lee Milligan	Principal Accounting Officer	N/A	N/A	N/A
Dr. Rajesh Manchanda Ph.D.	Chief Technical Operations Officer	N/A	N/A	1966
Mr. Nicholas Brandon Ph.D.	Chief Scientific Officer	N/A	N/A	1974

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Neumora Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.